Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISTA: Apixaban vs Warfarin for Cognitive Decline in Atrial Fibrillation
NCT03839355Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of apixaban in Atrial fibrillation (AFib), sponsored by Mayo Clinic. Started Dec 2018; status: terminated.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03839355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03839355.